Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia

Anna Hecht, Julia A. Meyer, Astrid Behnert, Eric Wong, Farid Chehab, Adam Olshen, Aaron Hechmer, Catherine Aftandilian, Rukhmi Bhat, Sung Won Choi, Satheesh Chonat, Jason E. Farrar, Mark Fluchel, Haydar Frangoul, Jennifer H. Han, Edward A. Kolb, Dennis J. Kuo, Margaret L. MacMillan, Luke Maese, Kelly W. MaloneyAru Narendran, Benjamin Oshrine, Kirk R. Schultz, Maria L. Sulis, David van Mater, Sarah K. Tasian, Wolf Karsten Hofmann, Mignon L. Loh, Elliot Stieglitz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Mutations in the CBL gene were first identified in adults with various myeloid malignancies. Some patients with juvenile myelomonocytic leukemia (JMML) were also noted to harbor mutations in CBL, but were found to have generally less aggressive disease courses compared to patients with other forms of Ras pathway-mutant JMML. Importantly, and in contrast to most reports in adults, the majority of CBL mutations in JMML patients are germline with acquired uni-parental disomy occurring in affected marrow cells. Here, we systematically studied a large cohort of 33 JMML patients with CBL mutations and found that this disease is highly diverse in presentation and overall outcome. Moreover, we discovered somatically acquired CBL mutations in 15% of pediatric patients who presented with more aggressive disease. Neither clinical features nor methylation profiling were able to distinguish patients with somatic CBL mutations from those with germline CBL mutations, highlighting the need for germline testing. Overall, we demonstrate that disease courses are quite heterogeneous even among patients with germline CBL mutations. Prospective clinical trials are warranted to find ideal treatment strategies for this diverse cohort of patients.

Original languageEnglish (US)
Pages (from-to)178-186
Number of pages9
JournalHaematologica
Volume107
Issue number1
DOIs
StatePublished - Jan 2022

Funding

This work was supported by the National Institutes of Health, National Cancer Institute grants 1U54CA196519 (to MLL, ES); 1U01CA232486 (SKT); 1K08CA184418 (SKT); National Institutes of Health, National Heart, Lung, and Blood Institute grant K08HL135434 (ES); the Leukemia Lymphoma Society (MLL, ES); Cookies for Kids Cancer (MLL); Pediatric Cancer Research Foundation (ES); the V Foundation (ES); the UCSF Catalyst Program (ES); the California Cancer League (ES); the Frank A. Campini Foundation (MLL and ES); the Children’s Hospital of Philadelphia Center for Childhood Cancer Research (SKT) and the German Research Foundation HE 7682/1-1 (AH). Next-generation sequencing was supported by the Center for Advanced Technologies at UCSF and the Computational Biology and Informatics group at the UCSF HDFCCC (supported by NCI grant: 5P30CA082103). MLL is the Benioff Chair of Children’s Health and the Deborah and Arthur Ablin Endowed Chair for Pediatric Molecular Oncology at Benioff Children’s Hospital.

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia'. Together they form a unique fingerprint.

Cite this